ENOVEnovis Corporation

Healthcare

$17.71-45% 1Y

$17.71

$17.4452 weeks$32.87

Price

-45%1Y

End-of-day closes, not the intraday tick.

Survival is the story here: start there

Quality mixed, hard red flags, price roughly fair, growth steady, the market undecided.

RyuScore 14 of 100: see how it is built

What they do

Enovis Corporation (the “Company”, “Enovis”, “we” or “us”) is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing, and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. Our products address the continuum of patient care from injury prevention to rehabilitation after surgery or injury or from degenerative disease, enabling people to regain or maintain their natural motion.

In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR

P/En/a

Market value$1.27B

1 year-45%

5 years-78%

Charts

As reported to the SEC, without any scoring.

Enovis Corporation (ENOV) reported revenue of $583M in Q2 2026 (quarter ended Jul 3, 2026), up 3.2% from the same quarter a year earlier. That came with a gross margin of 62% and net loss of $1.2M. For the full year FY2025, revenue was $2.25B (+6.7% year on year) and net income −$1.18B. Its largest product in Q2 2026 was Surgical at $138M, 32% of the disclosed total, just ahead of Bracing And Support at 30%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

Sep 1, 2026Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical.Regulation FD disclosure · press release
May 19, 2026Approval of an Amendment to the Enovis Corporation 2020 Omnibus Incentive Plan At the Annual Meeting of Stockholders of Enovis Corporation (the “Company”) held on May 19, 2026 (the “Annual Meeting”), the Company’s stockholders voted on and approved an amendment to the Company’s 2020 Omnibus Incentive Plan (the “2020 …Director or officer change · Form 8-K
Dec 15, 2025On December 10, 2025, Patricia A. Lang informed the Board of Directors of Enovis Corporation (the “Company”) of her intention to retire from her current position as the Company’s Senior Vice President and Chief Human Resources Officer on April 3, 2026.Director or officer change · Form 8-K